A carregar...
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis(®) (ranibizumab), Eylea(®) (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in...
Na minha lista:
| Publicado no: | Clin Ophthalmol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6207386/ https://ncbi.nlm.nih.gov/pubmed/30498330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S180393 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|